{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-027860","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.293819+00:00","generated_at":"2026-06-28T09:42:19.490062+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Interpace Q3 revenue $9.5M, net loss $3.6M; new $7.5M facility, $8M term loan, $30M rights offering","bullets":["Q3 revenue $9.5M (+15% YoY); loss from continuing ops $(3.5)M vs $(6.2)M; adjusted EBITDA $(1.8)M vs $(2.9)M.","Cash collections $10.4M (2nd consecutive record quarter); DSO down 48% YoY to 59 days; cash $3.2M at Sep 30.","Entered $7.5M Comerica revolver (matures Sep 2023) and $8M BroadOak term loan to repay private equity bridge loans.","Proposed $30M rights offering (backstopped by 3K Limited Partnership) to fund growth; goal $100M revenue run rate by 2023.","Expanded payor contracts: 54 commercial payors for thyroid tests; two new patents granted for ThyraMIR and PancraGEN technologies."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-027860","json":"https://secwatch.observer/filing/0001493152-21-027860.json","markdown":"https://secwatch.observer/filing/0001493152-21-027860.md","text":"https://secwatch.observer/filing/0001493152-21-027860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315221027860/0001493152-21-027860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315221027860/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:42:19.490062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}